despit
year
research
precis
determin
coronaviru
replic
pathogenesi
remain
unidentifi
known
pathogenesi
sever
acut
respiratori
syndrom
coronaviru
sarscov
limit
clinic
observ
suggest
viralinduc
cytotox
host
immunemedi
destruct
contribut
sever
diseas
summari
discuss
recent
advanc
coronaviru
research
facilit
identif
crucial
molecular
target
ration
design
sar
therapeut
sar
coronaviru
came
dramat
attent
fatal
potenti
pandem
respiratori
diseas
scientif
respons
swift
effect
etiolog
agent
identifi
genom
clone
sequenc
larg
stride
made
understand
key
point
viral
life
cycl
includ
recent
identif
function
host
cell
receptor
solut
threedimension
structur
viral
attach
protein
much
progress
possibl
foundat
basic
coronaviru
biolog
exist
denison
laboratori
forefront
small
group
investig
dissect
basic
featur
coronavirus
denison
discov
critic
mechan
life
cycl
coronavirus
key
figur
effect
urgent
applic
knowledg
sar
histor
coronavirus
regard
sever
human
pathogen
ill
primarili
limit
mild
upper
respiratori
infect
compris
annual
common
cold
worldwid
howev
recent
identif
novel
human
coronaviru
etiolog
agent
sever
acut
respiratori
syndrom
sar
dramat
demonstr
potenti
viru
famili
caus
devast
potenti
pandem
diseas
well
econom
social
disrupt
although
coronaviru
replic
pathogenesi
focu
mani
year
research
numer
dedic
investig
mani
unansw
question
remain
exactli
virus
prolifer
host
organ
bring
diseas
see
outstand
issu
chief
import
question
inhibit
coronavirusinduc
diseas
sar
present
clinic
proven
treatment
sar
care
infect
person
mostli
empir
review
give
brief
descript
coronaviru
replic
sar
coronaviru
sarscov
pathogenesi
describ
current
therapi
treat
sar
highlight
recent
advanc
identif
crucial
molecular
target
ration
design
antivir
therapeut
patient
diagnos
sar
exhibit
atyp
pneumonia
lower
respiratori
tract
infect
associ
pulmonari
lesion
alveolar
damag
mononuclear
infiltr
presenc
larg
multinucl
cell
lung
although
detail
studi
sarscov
pathogenesi
clinic
progress
sar
shown
follow
triphas
pattern
earlystag
symptom
last
approxim
day
includ
fever
gener
myalgia
coupl
increas
viral
load
phase
symptom
thought
primarili
consequ
viralinduc
cytopath
effect
midstag
diseas
occur
day
reveal
increas
fever
occurr
diarrhea
accompani
slight
decreas
viral
load
specif
antibodi
sarscov
detect
patient
sera
stage
diseas
progress
suggest
viral
replic
well
host
immun
respons
might
contribut
ill
latestag
infect
clinic
worsen
occur
associ
decreas
viral
shed
nearli
patient
suffer
acut
respiratori
distress
syndrom
ard
requir
ventilatori
support
latestag
infect
lung
immunopatholog
damag
sever
lymphopenia
propos
direct
result
excess
immun
respons
viral
replic
host
immun
respons
hypothes
contribut
pathogenesi
sarscov
import
understand
aspect
viru
biolog
defin
potenti
therapeut
combin
direct
antivir
immun
modul
viral
factor
influenc
diseas
might
includ
serv
sole
purpos
enhanc
virul
much
like
toxin
well
factor
caus
cytotox
effect
host
cell
mere
consequ
viral
replic
date
individu
sar
protein
known
function
potenti
virul
factor
identifi
therefor
discuss
limit
molecular
determin
coronaviru
replic
viruscel
interact
occur
replic
suspect
contribut
pathogenesi
involv
immun
system
enhanc
sever
coronaviru
diseas
known
damag
infect
cell
caus
coronaviru
replic
impact
sever
diseas
three
main
cytopath
effect
coronaviru
replic
host
cell
syncytia
multinucl
cell
format
initi
apoptosi
program
cell
death
induct
cellular
autophagi
degrad
intracellular
compon
lysosom
mani
coronavirus
syncytia
format
hallmark
infect
replic
cell
cultur
syncytia
form
result
cellcel
fusion
caus
viral
attach
protein
spike
locat
infect
cell
surfac
bind
receptor
adjac
cell
lung
patholog
sar
patient
note
presenc
syncytia
howev
sarscov
caus
vero
african
green
monkey
kidney
cell
becom
multinucl
cultur
remain
unknown
whether
cellcel
fusion
event
disrupt
normal
cellular
process
lead
cytotox
apoptosi
anoth
potenti
detriment
effect
coronaviru
replic
one
report
show
increas
number
apoptot
cell
spleen
lung
lymph
node
sar
patient
compar
normal
tissu
apoptot
cell
includ
pneumocyt
lymphocyt
monocyt
despit
increas
program
cell
death
still
numer
infect
tissu
coronavirusinduc
apoptosi
studi
greater
detail
model
coronaviru
mous
hepat
viru
mhv
specif
relat
demyelin
central
nervou
system
cn
mice
one
studi
reveal
mhv
induc
apoptosi
oligodendrocyt
upon
entri
viru
cell
process
requir
ongo
viral
replic
presum
induct
program
cell
death
mediat
either
signal
via
cell
surfac
receptor
activ
upon
viru
attach
entri
caus
directli
compon
incom
coronaviru
virion
support
latter
shown
express
sar
structur
protein
nucleocapsid
cultur
cell
lead
reorgan
actin
cytoskeleton
induct
apoptosi
appar
whether
initi
apoptosi
benefici
coronaviru
replic
instead
byproduct
viral
entri
contrast
activ
host
cell
autophagi
pathway
normal
involv
protein
membran
recycl
actual
requir
effici
replic
mhv
mhv
probabl
coronavirus
induc
format
intracellular
doublemembran
vesicl
serv
scaffold
viral
enzym
doublemembran
vesicl
deriv
host
cell
autophagosom
inhibit
compon
autophagi
pathway
disrupt
viral
replic
mhv
infect
increas
amount
cellular
protein
degrad
activ
autophagi
consequ
process
could
sever
cytotox
effect
cell
contribut
viral
pathogenesi
capac
viru
modul
immun
respons
pivot
effect
cours
diseas
fate
infect
host
sever
lung
inflamm
macrophag
infiltr
lymphopenia
seen
sar
patient
suggest
host
immun
respons
contribut
significantli
high
morbid
mortal
sar
still
known
immun
system
highli
induc
upon
infect
sarscov
probabl
adapt
immun
respons
play
role
sar
pathogenesi
howev
robust
activ
innat
respons
specif
inflamm
seem
devast
term
exacerb
diseas
elev
level
proinflammatori
cytokin
chemic
signal
recruit
immun
cell
infect
tissu
detect
sarscovinfect
person
exampl
pediatr
sar
patient
show
markedli
elev
level
cytokin
primari
mediat
inflamm
also
implic
cellular
apoptosi
recent
studi
adult
sar
patient
demonstr
sever
symptom
worsen
level
promot
antibodyproduc
b
cell
increas
wherea
level
tgfb
inhibit
immun
cell
activ
decreas
mhv
innat
immun
respons
implic
neuropatholog
seen
infect
mice
particular
capac
differ
strain
mhv
differenti
stimul
cytokin
releas
cn
direct
type
infiltr
leukocyt
popul
alter
sever
viral
enceph
result
studi
support
content
cytokin
dysregul
coronaviru
infect
might
account
least
part
sever
clinic
diseas
date
clinic
proven
therapi
coronaviru
infect
anim
human
acut
sar
epidem
sever
high
mortal
diseas
led
use
numer
often
combin
empir
antivir
drug
immun
modul
therapi
specif
base
clinic
observ
infer
patient
infect
sarscov
treat
steroid
inhibit
inflamm
antivir
ribavirin
nucleosid
analog
proven
clinic
effect
sever
rna
virus
limit
clinic
virolog
measur
lack
control
studi
make
difficult
draw
conclus
regard
efficaci
ribavirin
steroid
therapi
significantli
lessen
sever
sar
preliminari
studi
use
interferonalpha
infa
combin
corticosteroid
associ
rapid
resolut
radiograph
lung
abnorm
interferon
inhibit
viral
infect
activ
immun
cell
alter
intracellular
environ
restrict
viral
replic
thu
make
good
candid
therapeut
moreov
one
studi
report
administr
human
immunoglobulin
convalesc
patient
sera
show
clinic
benefit
suggest
antibodi
sarscov
might
decreas
viral
load
known
antivir
target
viral
enzym
proteinas
also
test
potenti
inhibitor
coronaviru
replic
cystein
proteinas
inhibitor
shown
dramat
reduc
sarscov
replic
cell
cultur
condit
addit
human
immunodefici
viru
hiv
aspart
acid
proteinas
inhibitor
lopinavirritonavir
decreas
sarscov
replic
vitro
associ
reduc
morbid
mortal
infect
patient
compar
untreat
individu
base
preliminari
report
evalu
lopinavirritonavir
use
control
studi
warrant
current
understand
basic
coronaviru
biolog
base
year
research
cadr
commit
investig
provid
molecular
basi
design
new
antivir
specif
major
known
concern
intracellular
coronaviru
replic
determin
use
mhv
model
system
although
detail
sarscov
replic
remain
determin
similar
mhv
sarscov
level
replicas
protein
enzym
replic
viral
rna
suggest
two
virus
similar
intracellular
replic
process
thu
know
mhv
appli
develop
drug
target
sarscov
replic
machineri
tabl
coronaviru
replic
initi
bind
viral
attach
protein
spike
specif
receptor
surfac
host
cell
entri
viral
genom
positivestrand
rna
cytoplasm
fig
molecul
involv
viral
attach
entri
repres
first
target
inhibit
viral
lifecycl
type
receptor
util
differ
coronavirus
primari
determin
capac
virus
replic
within
specif
cell
type
tissu
sarscov
angiotensinconvert
enzym
identifi
function
receptor
fact
express
numer
tissu
human
bodi
support
observ
sarscov
detect
blood
lung
liver
kidney
one
report
character
determin
sar
cov
entri
cell
threedimension
crystal
structur
spike
viral
attach
protein
solv
studi
provid
blueprint
develop
inhibitor
viral
entri
probabl
target
spike
glycoprotein
viral
receptor
follow
entri
genom
rna
molecul
cytoplasm
next
stage
viru
lifecycl
gener
viral
protein
requir
rna
synthesi
enzym
protein
involv
synthesi
viral
rna
theori
inhibit
without
detriment
effect
host
cell
thu
ideal
target
antivir
coronavirus
gener
protein
requir
viral
rna
synthesi
first
larg
polyprotein
subsequ
cleav
smaller
product
viralencod
cystein
proteinas
among
matur
protein
product
rnadepend
rna
polymeras
rdrp
rna
helicas
sever
put
rna
process
enzym
hypothes
matur
protein
must
newli
translat
process
function
viral
rna
synthesi
specif
addit
proteinas
inhibitor
anytim
mhv
lifecycl
abolish
viral
rna
synthesi
halt
replic
result
combin
clinic
vitro
studi
proteinas
inhibitor
sarscov
suggest
viral
proteinas
principl
target
drug
design
determin
crystal
structur
sarscov
main
picornaviru
proteinas
facilit
design
drug
elucid
determin
inhibitor
bind
moreov
bioinformat
model
catalyt
core
sarscov
rdrp
propos
allow
insight
structur
function
key
viral
enzym
rna
synthesi
import
target
protein
involv
format
membran
cytoplasm
viral
replic
complex
serv
scaffold
viral
protein
mediat
rna
synthet
activ
cell
engin
delet
autophagi
gene
atg
unabl
form
autophagosom
well
viralinduc
doublemembran
vesicl
cell
support
effici
viral
replic
suggest
compon
cellular
autophagi
pathway
target
antivir
develop
assembl
releas
coronaviru
virion
host
cell
final
stage
viral
lifecycl
although
molecular
determin
coronaviru
assembl
releas
well
character
process
repres
addit
target
inhibit
replic
follow
viral
rna
synthesi
cytoplasm
newli
synthes
genom
rna
molecul
transport
site
virion
particl
assembl
unknown
mechan
mhv
viru
assembl
bud
occur
endoplasmicreticulumgolgi
intermedi
compart
ergic
sever
mhv
protein
includ
helicas
nucleocapsid
protein
also
transloc
ergic
time
particl
assembl
thought
involv
deliveri
rna
packag
newli
bud
viru
thu
inhibit
capac
helicas
nucleocapsid
deliv
genom
rna
molecul
ergic
would
probabl
hinder
particl
assembl
traffick
assembl
coronavirus
cell
surfac
releas
well
understood
presum
occur
normal
exocyt
process
although
sar
outbreak
control
likelihood
possibl
human
anim
reservoir
suggest
viru
continu
pose
worldwid
public
health
threat
understand
biolog
pathogenesi
coronavirus
crucial
develop
antivir
therapeut
potenti
intervent
case
sarscov
reemerg
drug
probabl
target
factor
involv
cellular
destruct
caus
viral
replic
well
factor
influenc
immunemedi
damag
highest
prioriti
given
develop
sarscov
spike
glycoprotein
orang
bind
cellular
receptor
red
follow
entri
rna
genom
blue
cytoplasm
larg
replicas
polyprotein
gray
rectangl
gener
cleav
smaller
product
gray
circl
stage
viral
proteinas
encod
polyprotein
respons
cleavag
next
matur
protein
induc
format
viral
replic
complex
surfac
intracellular
doublemembran
vesicl
stage
membran
vesicl
function
scaffold
viral
enzym
rnadepend
rna
polymeras
rdrp
mediat
viral
rna
synthesi
stage
newli
synthes
genom
deliv
virion
particl
assembl
site
stage
mhv
virion
assembl
bud
endoplasmicreticulumgolgi
compart
ergic
stage
coronaviru
virion
releas
cell
via
exocyt
pathway
stage
antivir
block
sarscov
replic
inhibitor
earli
step
viru
lifecycl
could
block
earlyand
midstag
cytopath
effect
possibl
decreas
immunopatholog
damag
observ
sarscovinfect
person
sinc
last
identifi
natur
occur
case
sar
juli
remark
progress
made
studi
identifi
target
interfer
viru
replic
identifi
potenti
therapeut
sarscov
develop
anim
model
replic
pathogenesi
test
potenti
vaccin
candid
recent
comprehens
studi
natur
synthet
compound
assay
capac
inhibit
sarscov
replic
cell
cultur
screen
identifi
approxim
put
antivir
current
clinic
develop
suggest
cure
sar
might
closer
thought
question
remain
develop
test
therapeut
vaccin
sustain
sar
appear
retreat
unknown
endem
host
caus
human
diseas
answer
question
ye
sever
reason
first
isol
case
sar
sinc
juli
result
labassoci
infect
also
possibl
de
novo
transmiss
anim
human
recent
case
china
attest
characterist
sarscov
result
worldwid
epidem
one
make
possibl
reemerg
includ
rel
long
incub
period
nonspecif
prodrom
variabl
effici
transmiss
second
natur
host
mechan
introduct
mainten
human
known
thu
import
strategi
implement
case
new
outbreak
third
mani
strategi
test
probabl
applic
coronavirus
human
anim
thu
potenti
import
right
final
discuss
sarscov
biosafeti
biosecur
inadvert
possibl
intent
outbreak
therefor
essenti
understand
target
therapeut
defin
strategi
prevent
summari
applic
knowledg
concern
clinic
manifest
coronaviru
diseas
molecular
determin
coronaviru
replic
provid
foundat
rapid
develop
effect
inhibitor
pathogen
virus
